Business Description
Gennbio Inc
ISIN : KR7072520000
Compare
Compare
Traded in other countries / regions
072520.Korea IPO Date
2004-10-29Description
Gennbio Inc builds drug and bio long-term development platform. The company produces models of primate diseases such as organ transplants and immune or diabetic models.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Equity-to-Asset | 0.64 | |||||
| Debt-to-Equity | 0.34 | |||||
| Debt-to-EBITDA | -3.62 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -2.83 | |||||
| Beneish M-Score | 0.95 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -39.1 | |||||
| 3-Year EBITDA Growth Rate | 52.7 | |||||
| 3-Year EPS without NRI Growth Rate | 39.6 | |||||
| 3-Year FCF Growth Rate | 40.7 | |||||
| 3-Year Book Growth Rate | -13.2 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 33.63 | |||||
| 12-1 Month Momentum % | 2.37 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.99 | |||||
| Quick Ratio | 0.99 | |||||
| Days Inventory | 39.49 | |||||
| Days Sales Outstanding | 1957.71 | |||||
| Days Payable | 267.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -34.2 | |||||
| Shareholder Yield % | 76.19 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -132.02 | |||||
| Operating Margin % | -1748.22 | |||||
| Net Margin % | -2784.83 | |||||
| FCF Margin % | -1366.54 | |||||
| ROE % | -14.55 | |||||
| ROA % | -9.13 | |||||
| ROIC % | -6.1 | |||||
| ROC (Joel Greenblatt) % | -10.35 | |||||
| ROCE % | -9.98 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 64.13 | |||||
| PB Ratio | 0.43 | |||||
| Price-to-Tangible-Book | 0.49 | |||||
| EV-to-EBIT | -5.87 | |||||
| EV-to-EBITDA | -8.2 | |||||
| EV-to-Revenue | 138.91 | |||||
| EV-to-FCF | -10.16 | |||||
| Price-to-Median-PS-Value | 14.28 | |||||
| Earnings Yield (Greenblatt) % | -17.04 | |||||
| FCF Yield % | -17.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gennbio Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 371.834 | ||
| EPS (TTM) (â‚©) | -149 | ||
| Beta | 1.02 | ||
| Volatility % | 20.78 | ||
| 14-Day RSI | 33.63 | ||
| 14-Day ATR (â‚©) | 0.000043 | ||
| 20-Day SMA (â‚©) | 389 | ||
| 12-1 Month Momentum % | 2.37 | ||
| 52-Week Range (â‚©) | 365 - 880 | ||
| Shares Outstanding (Mil) | 74.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gennbio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gennbio Inc Stock Events
| Event | Date | Price(â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gennbio Inc Frequently Asked Questions
What is Gennbio Inc(XKRX:072520)'s stock price today?
The current price of XKRX:072520 is â‚©389.00. The 52 week high of XKRX:072520 is â‚©880.00 and 52 week low is â‚©365.00.
When is next earnings date of Gennbio Inc(XKRX:072520)?
The next earnings date of Gennbio Inc(XKRX:072520) is .
Does Gennbio Inc(XKRX:072520) pay dividends? If so, how much?
Gennbio Inc(XKRX:072520) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers